RASAL2 Plays Inconsistent Roles in Different Cancers

RAS protein activator like 2 (RASAL2) belongs to the RAS GTPase-activating protein family and plays an important role in several cancers, including ovarian cancer, nasopharyngeal carcinoma, malignant astrocytoma, renal cell carcinoma, bladder cancer, colorectal cancer, liver cancer, triple-negative breast cancer, lung adenocarcinoma, and pancreatic ductal adenocarcinoma. Traditionally, RASAL2 has been regarded as a tumor suppressor but recent studies have found that it is an oncogene in specific types of cancer, such as colorectal cancer, liver cancer, triple-negative breast cancer, triple-negative/estrogen receptor-negative breast cancer. In this review, we summarize the latest findings regarding RASAL2 in cancers, which may be important and useful in clinical practice. We discussed the specific functions and mechanisms of RASAL2 in different kinds of cancer cells (including its inhibition of invasion, metastasis and angiogenesis and its opposite effects), which may provide new directions for cancer research and treatments. RASAL2 exhibits different relationship with clinical cancer stage, histological grade, prognosis and overall survival in different kinds of tumor. RASAL2 is a potential prognostic factor and a new therapeutic target for diagnosis and treatment.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 24 October 2019Source: Practical Radiation OncologyAuthor(s): Bram D. Vermeulen, Paul M. Jeene, Jasmijn Sijben, Robin Krol, Heidi Rütten, Johannes A. Bogers, Pètra M. Braam, Peter D. SiersemaAbstractPurposeClinical evidence regarding optimal radiation dose for palliation of dysphagia from esophageal cancer is generally lacking. In an effort to investigate optimal radiation dose, we assessed 2 different radiation schedules for palliation of dysphagia.Methods and MaterialsWe performed a multicenter, retrospective study comparing low-dose radiation therapy (LR: 5 x 4 Gy external ...
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 4 December 2019Source: Journal of Geriatric OncologyAuthor(s): Birgit van Ee, Joris Slaets, Carolien Smits, Aafke Honkoop, Ad Kamper, Mariët Hagedoorn
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 4 December 2019Source: Cancer EpidemiologyAuthor(s): Ashley E. Stenzel, Kirsten B. Moysich
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
ConclusionWe have shown that GP-identified instances of avoidable delay have construct validity. Whilst the causes of avoidable diagnostic delays are multi-factorial and occur in different settings and phases of the diagnostic process, their analysis can guide improvement initiatives and enable the examination of any prognostic implications.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Hyperthermic Mitomycin using the HIVEC® device is a rather safe and well tolerated treatment. Efficiency remains partial as 27.3% of patients experienced recurrence during the first year. These data should be confirmed by prospective multicentric studies. PMID: 31787540 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
The US Food and Drug Administration approved the immunotherapy as initial treatment of metastatic nonsquamous non-small cell lung cancer (mNSCLC).Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Publication date: 15 February 2020Source: Materials Chemistry and Physics, Volume 242Author(s): A.S. Rajashekharaiah, G.P. Darshan, H.B. Premkumar, P. Lalitha, S.C. Sharma, H. NagabhushanaAbstractNano biotechnology is rapidly growing eco-friendly research area and used in various broad sections, such as biology, chemistry, physics, biomedicine and material engineering. The synthesis of highly efficient, non-toxic, inexpensive and environmental friendly nanomaterial is an urgent need. The aim of the present work was assessment of anti-oxidant, anti-bacterial and cytotoxicity potentials of Bi2Zr2O7:Dy3+ (1–11 mol ...
Source: Materials Chemistry and Physics - Category: Materials Science Source Type: research
Publication date: 3 December 2019Source: Cell Reports, Volume 29, Issue 10Author(s): Brett S. Marro, Jaroslav Zak, Reza Beheshti Zavareh, John R. Teijaro, Luke L. Lairson, Michael B.A. OldstoneSummaryInhibitory receptors (IRs) function as critical regulators of immune responses by tempering T cell activity. In humans, several persisting viruses as well as cancers exploit IR signaling by upregulating IR ligands, resulting in suppression of T cell function (i.e., exhaustion). This allows escape from immune surveillance and continuation of disease. Here, we report the design, implementation, and results of a phenoty...
Source: Cell Reports - Category: Cytology Source Type: research
Publication date: 3 December 2019Source: Cell Reports, Volume 29, Issue 10Author(s): Assaf Magen, Jia Nie, Thomas Ciucci, Samira Tamoutounour, Yongmei Zhao, Monika Mehta, Bao Tran, Dorian B. McGavern, Sridhar Hannenhalli, Rémy BosselutSummaryMost current tumor immunotherapy strategies leverage cytotoxic CD8+ T cells. Despite evidence for clinical potential of CD4+ tumor-infiltrating lymphocytes (TILs), their functional diversity limits our ability to harness their activity. Here, we use single-cell mRNA sequencing to analyze the response of tumor-specific CD4+ TILs and draining lymph node (dLN) T cells. Co...
Source: Cell Reports - Category: Cytology Source Type: research
More News: Adenocarcinoma | Astrocytoma | Bladder Cancer | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Hepatocellular Carcinoma | Kidney Cancer | Liver | Liver Cancer | Nasopharyngeal Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology